Arvinas Inc is a pioneering biotech firm focused on developing innovative treatments by targeting disease-causing proteins for degradation. Utilizing its proprietary PROTAC technology, Arvinas is advancing a novel class of therapies, including potential treatments for prostate cancer and breast cancer. With ongoing clinical trials and strategic partnerships with major pharmaceutical companies, Arvinas is at the forefront of leveraging the body's natural processes to fight serious diseases. Founded in 2013, the company is headquartered in New Haven, Connecticut, marking a significant player in the biotechnology industry.
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Here are the top analysts calls for Friday, November 25.
Tuesday's top analyst upgrades and downgrades included Apple, Chipotle Mexican Grill, Citigroup, Constellation Energy, Fastenal, JPMorgan Chase, Kroger, Livent, News Corp, Prologis, Salesforce and SunPower.
Tuesday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Costco Wholesale, Dollar General, Exxon Mobil, FedEx, Horizon Therapeutics, Hyatt Hotels, Lucid, Medtronic, Micron Technology, Salesforce, Six Flags Entertainment, Tellurian and Unity Software.
Monday’s additional top analyst upgrades and downgrades were on Domino’s, iHeartMedia, Match Group, Virgin Galactic and more.
